Form 4 for ABOS Acumen Pharmaceuticals, Inc.
Accepted 2024-01-19 00:00:00 ET · period of report 2024-01-19 · accession 0001576885-24-000029 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-01-19 | 2024-01-19 | ABOS | OConnell Daniel Joseph | Pres, CEO, Dir | S - Sale | $3.47 | -15.2K | 502.5K | -3% | -$52.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-01-19 | S | D | 15,200 | $3.47 | 502,485 | D | — | — | (F1) Represents the number of shares sold by the Reporting Person in connection with the vesting of restricted stock units ("RSUs") pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2023. (F2) The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $3.3950 to $3.6500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |